TABLE OF CONTENTS
Volume 16, Issue 11 (November 2009)
Mini Review
Comparative assessment of siRNA and shRNA off target effects: what is slowing clinical development
D D Rao, N Senzer, M A Cleary and J Nemunaitis
Cancer Gene Ther 16: 807-809; advance online publication, August 28, 2009; doi:10.1038/cgt.2009.53
Original Articles
RNA interference-mediated knockdown of p21WAF1 enhances anti-tumor cell activity of oncolytic adenoviruses CGTOpen
M Shiina, M D Lacher, C Christian and W M Korn
Cancer Gene Ther 16: 810-819; advance online publication, May 1, 2009; doi:10.1038/cgt.2009.29
Lentiviruses with trastuzumab bound to their envelopes can target and kill prostate cancer cells
K-x Zhang, M Moussavi, C Kim, E Chow, I S Chen, L Fazli, W Jia and P S Rennie
Cancer Gene Ther 16: 820-831; advance online publication, April 17, 2009; doi:10.1038/cgt.2009.28
Cytotoxicity of adenoviruses expressing the wild-type p53 gene to esophageal carcinoma cells is linked with the CAR expression level and indirectly with the endogenous p53 status
G Ma, K Kawamura, Q Li, N Suzuki, M Liang, M Namba, H Shimada and M Tagawa
Cancer Gene Ther 16: 832-840; advance online publication, April 10, 2009; doi:10.1038/cgt.2009.21
Combination of human tumor necrosis factor-alpha (hTNF-
) gene delivery with gemcitabine is effective in models of pancreatic cancer
S R Murugesan, C R King, R Osborn, W R Fairweather, E M O'Reilly, M O Thornton and L L Wei
Cancer Gene Ther 16: 841-847; advance online publication, May 15, 2009; doi:10.1038/cgt.2009.32
Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas
L Vardouli, C Lindqvist, K Vlahou, A S I Loskog and A G Eliopoulos
Cancer Gene Ther 16: 848-860; advance online publication, May 22, 2009; doi:10.1038/cgt.2009.31
Novel strategies to augment genetically delivered immunotoxin molecular therapy for cancer therapy
X Liu, J Wu, S Zhang, C Li and Q Huang
Cancer Gene Ther 16: 861-872; advance online publication, May 22, 2009; doi:10.1038/cgt.2009.30
